Abstract 86P
Background
Autophagy achieves a tumor-suppressing function in the initial stages of cancer by eliminating protein aggregates and damaged organelles that might promote genomic instability and lead to tumor formation. Autophagy induced by hypoxia or metabolic stress also plays an important role in the regulation of inflammatory pathways. In cancer cells, this may lead to secretion of pro- and/ or anti-inflammatory cytokines and chemokines which may help the immune escape of the tumor. However, the underlying mechanism of autophagy-mediated modulation of anti-tumor immune response is not yet fully understood. Our aim is to investigate whether chemotherapy-induced autophagy-associated secretome has the potential to modulate the NK cell-mediated anti-tumor immune responses.
Methods
Initially, western blot and immunostaining analyses were performed for autophagy markers (LC3I/II and p62) to demonstrate that Etoposide (Eto) induces autophagy in MCF-7 cells. LC/MS-MS analysis was performed to determine the content of chemotherapy-induced autophagic secretome in supernatants of autophagy-induced MCF-7 cell cultures. Finally, how the chemotherapy-induced autophagic secretome effects the capacity of DNAM1-NK-92 cells to target MCF-7 cells was determined by degranulation assays.
Results
We demonstrated Etoposide (Eto) induces autophagy in MCF-7 cells as confirmed by detection of autophagy markers including LC3I/II and p62 by WB and by immunostaining analysis. LC/MS-MS results revealed that, metabolic enzymes, tumor antigens, chaperones and metastasis-related proteins were secreted during etoposide induced autophagy which could be reduced by use of Chloroquin. When wildtype or DNAM1 overexpressing NK-92 cells were treated with autophagic secretomes, it was observed that there were differences in the capacity of targeting MCF-7 cells.
Conclusions
This study provides new insights in the field of chemo-immunotherapy by characterizing the chemotherapy-induced autophagic secretome and determining its possible effect on NK cells.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
M.K. Kilic Eren.
Funding
Adnan Menderes University Scientific Research Foundation, The Scientific and Technological Research Council of Turkey.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
24P - Single cell transcriptomics of the immune cells during chemotherapy in triple-negative breast cancer patients
Presenter: Anastasia Frolova
Session: Poster session 09
25P - Role of AXL activation on adaptive resistance to KRAS-G12C inhibitors in KRAS-G12C-mutated non-small cell lung cancer
Presenter: Tadaaki Yamada
Session: Poster session 09
26P - Pre-clinical modelling and treatment of BRAF mutated colorectal cancer
Presenter: Mark White
Session: Poster session 09
27P - Extending a classification system for atypical BRAF mutations to improve targeted therapies in colorectal cancer cells
Presenter: Abhinav Madduri
Session: Poster session 09
28P - Xanthine oxidase as a prognostic factor in colorectal cancer metastatic disease
Presenter: Anton Burlaka
Session: Poster session 09
29P - The effect of cancer associated fibroblast-derived activin A on colorectal cancer progression
Presenter: Simone Stang
Session: Poster session 09
30P - Prostaglandin signaling in tumour stroma interaction in colorectal cancer and its impact on the secretome and functional relevance
Presenter: Mario Macia-Guardado
Session: Poster session 09
31P - Cell-free tumor microRNA as early biomarkers of high-grade cervical intraepithelial neoplasia using liquid biopsy
Presenter: Stéphanie Calfa
Session: Poster session 09
32P - Epigenetic reprogramming induced prostaglandin E2 accumulation via overactivated arachidonic acid metabolism during trastuzumab resistance formation of HER2-positive breast cancer
Presenter: yongmei yin
Session: Poster session 09
33P - Visualizing trastuzumab-deruxtecan action in HER2+ breast cancer cells at nanoscale
Presenter: Katia Cortese
Session: Poster session 09